Diffusion-Weighted Imaging for Predicting and Monitoring Primary Central Nervous System Lymphoma Treatment Response

References

1. 1.↵
   2. Nakajima S,
   3. Okada T,
   4. Yamamoto A, et al

   . Differentiation between primary central nervous system lymphoma and glioblastoma: a comparative study of parameters derived from dynamic susceptibility contrast-enhanced perfusion-weighted MRI. Clin Radiol 2015;70:1393–99 doi:10.1016/j.crad.2015.08.004 pmid:26382744

   CrossRefPubMed
2. 2.↵
   2. Bhagavathi S,
   3. Wilson JD

   . Primary central nervous system lymphoma. Arch Pathol Lab Med 2008;132:1830–34 pmid:18976024

   PubMedWeb of Science
3. 3.↵
   2. Kansara R,
   3. Shenkier TN,
   4. Connors JM, et al

   . Rituximab with high dose methotrexate in primary central nervous system lymphoma. Am J Hematol 2015;90:1149–54 doi:10.1002/ajh.24204 pmid:26414492

   CrossRefPubMed
4. 4.↵
   PDQ Adult Treatment Editorial Board. Primary CNS Lymphoma Treatment. Bethesda, Maryland: National Cancer Institute. Updated September 21, 2015. http://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq. Accessed June 9, 2016. pmid:26389274
5. 5.↵
   2. Barajas RF Jr.,
   3. Rubenstein JL,
   4. Chang JS, et al

   . Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 2010;31:60–66 doi:10.3174/ajnr.A1750 pmid:19729544

   Abstract/FREE Full Text
6. 6.↵
   2. Wieduwilt MJ,
   3. Valles F,
   4. Issa S, et al

   . Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res 2012;18:1146–55 doi:10.1158/1078-0432.CCR-11-0625 pmid:22228634

   Abstract/FREE Full Text
7. 7.↵
   2. Lee EJ,
   3. Lee SK,
   4. Agid R, et al

   . Preoperative grading of presumptive low-grade astrocytomas on MR imaging: diagnostic value of minimum apparent diffusion coefficient. AJNR Am J Neuroradiol 2008;29:1872–77 doi:10.3174/ajnr.A1254 pmid:18719036

   Abstract/FREE Full Text
8. 8.↵
   2. Guo AC,
   3. Cummings TJ,
   4. Dash RC, et al

   . Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002;224:177–83 doi:10.1148/radiol.2241010637 pmid:12091680

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Lee KC,
   3. Moffat BA,
   4. Schott AF, et al

   . Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res 2007;13:443–50 doi:10.1158/1078-0432.CCR-06-1888 pmid:17255264

   Abstract/FREE Full Text
10. 10.↵
    2. Morris PG,
    3. Correa DD,
    4. Yahalom J, et al

    . Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 2013;31:3971–79 doi:10.1200/JCO.2013.50.4910 pmid:24101038

    Abstract/FREE Full Text
11. 11.↵
    2. Abrey LE,
    3. Batchelor TT,
    4. Ferreri AJ, et al

    ; International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–43 doi:10.1200/JCO.2005.13.524 pmid:15955902

    Abstract/FREE Full Text
12. 12.↵
    2. Iwadate Y,
    3. Suganami A,
    4. Ikegami S, et al

    . Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature. J Neurooncol 2014;117:261–68 doi:10.1007/s11060-014-1379-4 pmid:24488444

    CrossRefPubMed
13. 13.↵
    2. Prasad SR,
    3. Jhaveri KS,
    4. Saini S, et al

    . CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology 2002;225:416–19 doi:10.1148/radiol.2252011604 pmid:12409574

    CrossRefPubMed
14. 14.↵
    2. Liua Y,
    3. Baia R,
    4. Suna H, et al

    . Diffusion-weighted imaging in predicting and monitoring the response of uterine cervical cancer to combined chemoradiation. Clin Radiol 2009;64:1067–74 doi:10.1016/j.crad.2009.07.010 pmid:19822239

    CrossRefPubMed
15. 15.↵
    2. Server A,
    3. Kulle B,
    4. Maehlen J, et al

    . Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema. Acta Radiol 2009;6:683–89 doi:10.1080/02841850902933123 pmid:19449234

    CrossRefPubMed
16. 16.↵
    2. Zacharia TT,
    3. Law M,
    4. Naidich TP, et al

    . Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging 2008;18:411–17 doi:10.1111/j.1552-6569.2007.00231.x pmid:18494774

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Africa E,
    3. Pauciulo A,
    4. Vadalà R, et al

    . Primary central nervous system lymphoma: role of DWI in the differential diagnosis. Rays 2005;30:221–26 pmid:16512067

    PubMed
18. 18.↵
    2. Wu X,
    3. Kellokumpu-Lehtinen PL,
    4. Pertovaara H, et al

    . Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma: a pilot study—comparison with 2-deoxy-2-fluoro-D-glucose-positron emission tomography/computed tomography. NMR Biomed 2011;24:1181–90 doi:10.1002/nbm.1689 pmid:21387451

    CrossRefPubMed
19. 19.↵
    2. Valles FE,
    3. Perez-Valles CL,
    4. Regalado S, et al

    . Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. AJNR Am J Neuroradiol 2013;34:35–40 doi:10.3174/ajnr.A3165 pmid:22936096

    Abstract/FREE Full Text
20. 20.↵
    2. Fujimoto H,
    3. Kazama T,
    4. Nagashima T, et al

    . Diffusion-weighted imaging reflects pathological therapeutic response and relapse in breast cancer. Breast Cancer 2014;21:724–31 doi:10.1007/s12282-013-0449-3 pmid:23400545

    CrossRefPubMed
21. 21.↵
    2. Chenevert TL,
    3. Stegman LD,
    4. Taylor JM, et al

    . Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029–36 doi:10.1093/jnci/92.24.2029 pmid:11121466

    Abstract/FREE Full Text
22. 22.↵
    2. Chenevert TL,
    3. McKeever PE,
    4. Ross BD

    . Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 1997;3:1457–66 pmid:9815831

    Abstract
23. 23.↵
    2. Moffat BA,
    3. Chenevert TL,
    4. Lawrence TS, et al

    . Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102:5524–29 doi:10.1073/pnas.0501532102 pmid:15805192

    Abstract/FREE Full Text
24. 24.↵
    2. Moffat BA,
    3. Hall DE,
    4. Stojanovska J, et al

    . Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA 2004;17:249–59 doi:10.1007/s10334-004-0079-z pmid:15580371

    CrossRefPubMed